Because of the poor solubility and permeability, ticagrelor (TGL), a P2Y12 receptor antagonist, has a low oral bioavailability and is therefore classed as a Biopharmaceutics classification system (BCS) class IV drug. The bioavailability of BCS class IV drugs can be increased with the help of liquid crystals, which act as an effective delivery mechanism. Hence, ticagrelor liquid crystals are prepared to enhance the oral bioavailability and antiplatelet activity of Ticagrelor. Central composite design is followed and the optimized formulation showed a particle size of 316.5nm and encapsulation efficiency of 87.98% and zeta potential of -23.1mV. Powder X-ray diffraction (PXRD) and Differential scanning calorimetry (DSC) were performed to detect the characteristics of TGL-LC. The invitro dissolution and exvivo permeation studies are performed between pure drug and ticagrelor liquid crystal formulation in which ticagrelor showed significantly best results compared to pure drug.